Oropharyngeal P16INK4A-negative squamous cell carcinoma

Clinical trials for Oropharyngeal P16INK4A-negative squamous cell carcinoma explained in plain language.

Never miss a new study

Get alerted when new Oropharyngeal P16INK4A-negative squamous cell carcinoma trials appear

Sign up with your email to follow new studies for Oropharyngeal P16INK4A-negative squamous cell carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Could immunotherapy boost radiation for head and neck cancer?

Disease control Paused

This study compares standard radiation plus cisplatin against two experimental approaches: radiation with docetaxel and cetuximab, or radiation with cisplatin and the immunotherapy drug atezolizumab. About 613 patients with high-risk stage III-IV head and neck cancer will partici…

Matched conditions: OROPHARYNGEAL P16INK4A-NEGATIVE SQUAMOUS CELL CARCINOMA

Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Sep 03, 2026 00:00 UTC

Oropharyngeal P16INK4A-negative squamous cell carcinoma

Get alerted when new Oropharyngeal P16INK4A-negative squamous cell carcinoma trials appear

Could immunotherapy boost radiation for head and neck cancer?